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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of evidence. 
BCG against coronavirus: less hype and more evidence, please 
Pai M. | Forbes | 12 April 2020 | Blog 
https://www.forbes.com/sites/madhukarpai/2020/04/12/bcg-against-coronavirus-less-hype-and-
more-evidence-please/#52e40db66b4f 
The hype around BCG is analogous to the hype around choloroquine and hydroxychloroquine for 
COVID-19 – hope of a silver bullet. But this blog highlights that ‘there is no evidence to support the 
clinical use of either BCG or hydroxychloroquine for COVID-19, except in carefully controlled 
clinical trials’. BCG has variable efficacy against pulmonary TB in adults (reported to range 
between 0 to 80%) but is still offered to infants in many mostly low- and middle-income countries 
where TB rates are high because trials show that BCG can protect children from severe, 
extrapulmonary forms of active TB disease. Global BCG vaccination policies and practices are 
mapped (last updated 2017) on the BCG World Atlas. A recent ‘flurry’ of ecological studies 
(currently pre-prints) claim a strong correlation between BCG vaccination and protection against 
COVID-19 but these studies have serious limitations which are described. BCG is inexpensive, 
safe and may have non-specific immune-boosting effects that might confer some protection 
against mortality by any cause so it is a lead worth following but through rigorous trials which are 
now underway in Australia, the Netherlands and the US with a focus on adults (e.g. healthcare 
workers) and from which results could be available within months. Note that this is not a vaccine 
specific for COVID-19 and cannot be administered to those with a compromised immune system 
as is a live-attenuated vaccine but may offer something generic globally in the meantime.  
The gendered dimensions of COVID-19 
The Lancet | 11 April 2020 | Editorial 
https://doi.org/10.1016/S0140-6736(20)30823-0 
Demographic data from small studies are already informing political decisions and clinical research 
strategies. Global Health 50/50 tracks sex-disaggregated infection and mortality COVID-19 data 
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from the 39 most-affected countries yet some countries, including the UK, the USA, Russia and 
Brazil, have yet to report such data. This Editorial joins the European Association of Science 
Editors and other organisations to urge all COVID-19 data to include age and sex. From those that 
have, it is unclear whether women or men are more likely to become infected, but more men are 
dying from COVID-19. Adverse outcomes of COVID-19 seem to be associated with comorbidities, 
including hypertension, cardiovascular disease and lung disease – conditions more prevalent in 
men and linked to smoking and drinking alcohol – behaviours associated with masculine norms. 
For women and girls, they are disproportionately affected in their wellbeing (including increased 
concerns over domestic violence) and economic resilience during lockdown. Women’s sexual and 
reproductive health services, including pre and post-natal care, are also disrupted. 
Neurologic manifestations of hospitalised patients with coronavirus disease 2019 in 
Wuhan China 
Mao et al. | JAMA | 10 April 2020 | Article 
https://doi.org/10.1001/jamaneurol.2020.1127 
In this retrospective, observational case series of data from 16 January 2020 to 19 February 2020 
of 214 consecutive hospitalised patients (mean [SD] age 52.7 [15.5] years, 40.7% men, 126 had 
non-severe infection and 88 patients had severe infection according to their respiratory status) with 
COVID-19 from three designated special care centres in Wuhan, China, 36.4% had neurologic 
manifestations and which were more common in patients with severe infection (45.5%) than in 
nonsevere patients (30.2%) according to their respiratory status. Compared with patients with non-
severe infection, patients with more severe infection had neurologic symptoms, which included 
acute cerebrovascular diseases (5 [5.7%] vs 1 [0.8%]), impaired consciousness (13 [14.8%] vs 3 
[2.4%]), and skeletal muscle injury (17 [19.3%] vs 6 [4.8%]). Clinicians should suspect SARS-CoV-
2 infection when seeing patients with neurologic manifestations as a differential diagnosis. 
The spectrum of neurologic disease in the severe acute respiratory syndrome coronavirus 
2 pandemic infection: neurologists move to the frontlines 
Pleasure et al | JAMA | 10 April 2020 | Editorial 
https://doi.org/10.1001/jamaneurol.2020.1065 
Given limited reports of neurologic complications of SARS, the study by Mao et al (above) is 
important. Neurological manifestations ranged from specific symptoms (e.g. loss of sense of smell 
or taste, myopathy and stroke) to more nonspecific symptoms (e.g. headaches, depressed level 
of consciousness, dizziness or seizure). Patients with some of the more common specific 
symptoms, including smell or taste impairment and myopathy, tended to have these symptoms 
earlier in their clinical course, distinct from SARS, where manifestations appeared quite late in 
established disease. 
Compassionate use of remdesivir for patients with severe COVID-19 
Grein et al | NEJM | 10 April 2020 | Article 
https://doi.org/10.1056/NEJMoa2007016 
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In a cohort of patients hospitalised for severe COVID-19 who were treated with compassionate-
use remdesivir, clinical improvement was observed in 36 of 53 patients. 
Note that there was no control group and this was not a randomised controlled trial. There is also 
discomfort in calling the use of an unproven and possibly harmful use of a drug ‘compassionate’. 
Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission 
Lighter et al. | Clinical Infectious Diseases | 9 April 2020 | Article 
https://doi.org/10.1093/cid/ciaa415 
This univariate retrospective analysis of data from COVID-19-positive symptomatic patients who 
presented to a large academic hospital system in New York City suggests that obesity in patients 
<60 years maybe a newly identified risk factor for hospital admission and need for critical care. 
Fear of a fragile planet 
Hossain N | IDS | 8 April 2020 | Opinion 
https://www.ids.ac.uk/opinions/fear-of-a-fragile-planet/ 
“Among the lessons of COVID-19 is the vital importance of political trust, of space for civil society 
and of strong communities in coping with health, social and economic shocks”. When powers are 
granted to governments there is concern that they can be hard to take back. Civil and political 
rights will be eroded as governments take on more power, but there are new opportunities to gain 
new rights, as governments take on responsibilities for supporting citizens in emergency support 
packages. When rights are granted these also can be hard to take back. “States that have failed 
to create space for civil society to thrive and grow now find they are faced with weak social allies 
in the fight against COVID-19”. Good citizen-state relationships are key to facing many global 
crises and building trust means citizens having the power to hold governments to account.  
Tracking COVID-19 cases 
Global 
WHO COVID-19 daily situation reports 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports 
Johns Hopkins University COVID-19 dashboard in real time 
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467
b48e9ecf6 
WEF: Visualisation tracking confirmed cases of COVID-19 as it spreads. Updated daily. 
https://wef-prod.earthtime.org/m/stories/2019_nCOV_infection 
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Vaccine Centre, LSHTM  
https://vac-lshtm.shinyapps.io/ncov_tracker/ 
This site complements the WHO and Johns Hopkins University COVID-19 dashboards by 
including the timeline functions, the ability to overlay past outbreaks, and an emphasis on 
normalised counts (per 100,000 individuals). 
Live data tracker: sex-disaggregated COVID-19 data from the 25 most-affected countries 
http://globalhealth5050.org/covid19 
Africa 
Coronavirus in Africa Tracker: How many covid-19 cases & where? 
https://africanarguments.org/2020/03/23/coronavirus-in-africa-tracker-how-many-cases-and-
where-latest/ 
UK 
PHE dashboard of UK COVID-19 Cases  
https://www.arcgis.com/apps/opsdashboard/index.html#/f94c3c90da5b4e9f9a0b19484dd4bb14 
Tools 
WhatsApp coronavirus information hub 
https://www.whatsapp.com/coronavirus 
CMMID Repository: Effectiveness of airport screening at detecting travellers infected with 
COVID-19 
https://cmmid-lshtm.shinyapps.io/traveller_screening/ 
App to model effectiveness of airport screening. 
Disability Inclusive Community Action – COVID-19 Matrix 
CBM | 30 March 2020 | Tool 
https://www.cbm.org/news/news/news-2020/cbm-develops-disability-inclusive-community-action-
covid-19-matrix/ 
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Online learning and events 
Online event: Policy modelling for COVID-19: Better data for better decision-making in low 
and middle-income countries 
Tuesday 14 April 2020 0900-1030 ET | Center for Global Development  
https://www.cgdev.org/event/policy-modelling-covid-19-better-data-better-decision-making-low-
and-middle-income-countries 
Moderator: Kalipso Chalkidou (CDG). Features Dan Ollendorf (CGD), Yot Teerawattananon 
(Thai Ministry of Public Health) and Anna Vassall (LSHTM) 
COVID-19 Diagnostics and Testing 
FIND, LSHTM & ASLM | FutureLearn course | Starts 20 April 2020 | 3 weeks | 3 hours weekly 
study | Free 
https://www.futurelearn.com/courses/covid-19-diagnostics-and-testing 
This course is designed for professionals involved in the testing and diagnosis of COVID-19, with 
a focus on low- and middle-income settings. You will learn the latest recommendations on COVID-
19 testing, get upt0date information on the performance of tests and how best to deploy them. 
COVID-19 Critical Care: Understanding and Application 
University of Edinburgh & Royal College of Physicians of Edinburgh  | FutureLearn course | 
Starts 6 April 2020 | 5 weeks | 1 hour weekly study | Free 
https://www.futurelearn.com/courses/covid-19-critical-care-education-resource 
Designed for frontline clinical staff to learn the principles and practice of critical care to treat and 
care for critically ill patients during the COVID-19 pandemic. You will learn (1) how to apply the 
current and evolving principles of PPE in the care of COVID-19; (2) apply evidence-based 
principles of advanced organ support and monitoring to the COVID-19 critically ill patients; (3) 
apply evidence-based daily practices to care of the critically ill patient; and (4) develop a range of 
specialised self-caring practices. 
Note that this resource has been created in response to the COVID-19 emergency and does not 
correspond to the classic structure of a FutureLearn course. You do not have to follow the week 
by week approach and can select the materials most relevant to your work. 
Emerging respiratory viruses, including COVID-19: methods for detection, prevention, 
response and control 
WHO | Free | 3 hours duration  
https://openwho.org/courses/introduction-to-ncov 
A general introduction to enable you to describe the fundamental principles of emerging 
respiratory viruses, including novel coronaviruses, and how to effectively respond to an outbreak. 
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Intended for public health professionals, incident managers and personnel working for the UN, 
international organisations and NGOs. 
Responding to COVID-19: Real-time training for the coronavirus disease outbreak 
WHO | Available now | multiple self-paced courses 
https://openwho.org/channels/covid-19 
Note that courses are available in English and other languages including French, Portuguese 
and Spanish. 
COVID-19: Tackling the Novel Coronavirus 
LSHTM | FutureLearn course | Starts 25 May 2020 | 3 weeks | 4 hours weekly study | Free 
https://www.futurelearn.com/courses/covid19-novel-coronavirus 
Unfacilitated access to this course remains. An updated version of this course will though be run 
from 25 May 2020. On this course you will learn what is known about the outbreak of COVID-19 
(week 1); what the practical implications for responding to COVID-19 are (week 2); and what we 
need to find out about COVID-19 (week 3). 
Resource Hubs 
WHO: Coronavirus disease (COVID-19) pandemic 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019 
Resources on coronavirus and disability 
https://asksource.info/covid-resources/search 
ODI Coronavirus: latest research and analysis on the implications of the coronavirus 
pandemic worldwide 
https://www.odi.org/our-work/coronavirus 
International Disability and Development Consortium and CORE Group: Repository of 
resources on disability inclusion and COVID-19 
https://docs.google.com/document/d/1IVP1u6yHfLuN9qNyLEct5-vtC0aqLKtKr-o-faAjves/edit 
US NIH online platform of all registered, ongoing clinical trials globally 
https://clinicaltrials.gov/ct2/results?cond=COVID-19 
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COVID-19 Narratives by Dr David Nabarro 
https://www.4sd.info/covid-19-narratives/ 
These narratives are being written by David Nabarro, Co-Director of the Imperial College Institute 
of Global Health Innovation at Imperial College London, Strategic Director for 4SD and one of six 
Special Envoys to the WHO DG Special Envoy on COVID-19, and peers to share with those who 
want more information about the situation and to help raise the awareness and readiness of all 
actors. Please visit WHO website for official guidance.  
Reliefweb COVID-19 
https://reliefweb.int/topics/covid-19 
Coronavirus global health emergency 
https://www.un.org/coronavirus 
Norwegian Institute of Public Health: Live map of COVID-19 evidence 
https://www.fhi.no/en/qk/systematic-reviews-hta/map/ 
Overview of scientific publications on COVID-19 categorised into subgroups to provide quick 
access to specific topic-relevant publications to help decision makers and research navigate the 
research and help identify research gaps.  
Vaccine Centre at LSHTM: COVID-19 vaccine development pipeline tracker 
https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/ 
COVID-19 Research Project Tracker by UKCDR & GloPID-R 
https://www.ukcdr.org.uk/funding-landscape/covid-19-research-project-tracker/ 
A live database of funded research projects across the world related to COVID-19 mapped against 
the priorities identified in the WHO Coordination Global Research Roadmap: 2019 Novel 
Coronavirus. 
WHO Q&A on COVID-19 
https://www.who.int/news-room/q-a-detail/q-a-coronaviruses 
Note that this resource includes Q&A on COVID-19; COVID-19, pregnancy, childbirth and 
breastfeeding; COVID-19, HIV and antiretrovirals; similarities and differences COVID-19 and 
influenza; mass gatherings and COVID-19; IPC for healthcare workers; COVID-19 and food and 
agriculture; smoking and COVID-19; malaria and COVID-19. 
COVID-19: Resources and research on epidemics and pandemics 
https://steps-centre.org/covid-19-coronavirus-resources-research-epidemics-pandemics/ 
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Stop TB Partnership TB and COVID-19 
http://www.stoptb.org/covid19.asp 
EPI-WIN: WHO information network for epidemics: COVID-19 public health emergency 
https://www.who.int/teams/risk-communication 
COVID-19: Research ethics 
https://ethicsresource.ringsgenderresearch.org/covid-19-resources/ 
LSTM: COVID-19 
https://www.lstmed.ac.uk/covid-19 
LSHTM: COVID-19 
https://www.lshtm.ac.uk/research/research-action/covid-19 
International Disability Alliance: COVID 19 and the disability movement 
http://www.internationaldisabilityalliance.org/content/covid-19-and-disability-movement 
Africa Centres for Disease Control and Prevention (Africa CDC) 
https://africacdc.org/covid-19/ 
UNICEF: Latest news and updates on coronavirus disease 2019 (COVID-19) 
https://www.unicef.org/coronavirus/covid-19 
Coronavirus: the science explained 
https://coronavirusexplained.ukri.org/en/ 
Social Science in Humanitarian Action: Updates on the novel COVID-19 outbreak 
https://www.socialscienceinaction.org/update-novel-covid-19-outbreak/ 
Special Collection: Coronavirus (COVID-19): evidence relevant to critical care 
https://www.cochrane.org/news/special-collection-coronavirus-covid-19-evidence-relevant-
critical-care 
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NICE UK: Rapid guidelines and evidence reviews  
https://www.nice.org.uk/covid-19 
Imperial College London MRC Centre for Global Infectious Disease Analysis COVID-19 
reports 
https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-coronavirus/ 
Global research on COVID-19 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-
coronavirus-2019-ncov 
WHO R&D Blueprint 
https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/ 
Latest information and advice from the UK Government 
https://www.gov.uk/guidance/coronavirus-covid-19-information-for-the-public 
CDC COVID-19 Resources 
https://www.cdc.gov/coronavirus/2019-ncov/index.htmlThe Global Health Network Coronavirus 
outbreak knowledge hub 
The Lancet COVID-19 Resource Centre 
https://www.thelancet.com/coronavirus 
Elsevier’s Novel Coronavirus Information Center 
https://www.elsevier.com/connect/coronavirus-information-center 
Cell Press Coronavirus Resource Hub 
https://www.cell.com/2019-nCOV 
Cochrane Special Collections - COVID-19: infection control and prevention measures 
https://www.cochranelibrary.com/collections/doi/SC000040/full 
The BMJ Coronavirus (covid-19): Latest news and resources 
https://www.bmj.com/coronavirus?int_source=wisepops&int_medium=wisepops&int_campaign=
DAA_CoronaVirus_Jan24 
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Johns Hopkins Coronavirus Resource Centre 
https://coronavirus.jhu.edu 
Global Partnership for Sustainable Development – COVID-19 resources 
http://www.data4sdgs.org/resources/covid-19-resources 
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